PRNewsWire
26 Mar 2026, 20:37 UTC · 26w ago
Verdict
Headline leans bearish. We score WGS −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
An FDA official reportedly labeled uniQure's lead gene therapy candidate, AMT-130, as a "failed therapy."
So whatDirect negative commentary from the primary regulator on a company's lead asset typically leads to severe devaluation of the stock.
More negative than 99% of claims this week
The FDA alleged that uniQure performed a "distorted or manipulated comparison" instead of a correct clinical study.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
A securities class action lawsuit alleges that uniQure misrepresented its interactions with the FDA and used an unapproved study design.
More negative than 91% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company faces a securities class action following a 49% stock price drop and a significant write-off.
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit and public rebukes from the FDA calling its lead therapy a 'failed therapy'.
More negative than 72% of ticker scores this week
The company announced the departure of its CEO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
+44.2%
Price is moving against the score
$88.48 vs $61.35 close before publication (Mar 26) · not market-adjusted
WGS chart →
